Purchase this article with an account.
L. A. Ramirez-Ponce, T. Valdez-Gonzalez, E. M. Lopez-Star, F. Martinez-Castro; Experience With Immunosuppresive Agents in Patients With Ocular Inflammatory Diseases. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4738.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
to evaluate the experience with immunosuppresive agents in patients with ocular inflammatory disease.
it is a descriptive, retrospective study, we included patients with ocular inflammatory diseases in treatment with oral immunosuppresive agents (azathioprine, methotrexate, cyclofosfamide, cyclosporine) from january 2004 to may 2007 treated in Fundacion Hospital Nuestra Senora de la Luz, Mexico.
We studied 89 patients, 54 % female, age average of 24,5 years old ( 3-82), the main diseases were: 33 patients with classic pars planitis, (37%), 23 patients with VKH syndrome (25%), 9 patients with scleritis (10%). The immunosuppresive agents used were: azathioprine in 61 patients (69%), with an average dose of 84,6 mg / day, duration of treatment 14,3 months, and reversible adverse effects in 14 patients (22.58%). Thirty one patients with methotrexate (34%) with an average dose of 9.8 mg/ week, average duration of treatment of 20 months, reversible adverse effects in 9 patients (29%), and in 1 patient irreversible adverse effects (3.2%). Cyclofosfamide in 24 patients (25%), average dose of 95.6 mg/day, average duration of treatment of 13,1 months, and reversible adverse effects in 14 patients (58%). Three patients were prescribed cyclosporin (3.3%), dose average of 208 mg/day, duration average of 6,6 months and reversible adverse effects in 1 patient.
Our population with different ocular inflammatory diseases were treated with different immunosuppresive agents, which 34% presented some reversible adverse effects, and only 1% with irreversible adverse effects.
This PDF is available to Subscribers Only